Navigating the Landscape of Precision Medicine in Gastric Cancer: FGFR2b Protein Overexpression as an Emerging Biomarker
Gastric and gastroesophageal junction (G/GEJ) cancers, otherwise known as stomach cancer, is the fourth leading cause of cancer-related death worldwide, with the highest incidence rates occurring in Eastern Asia and Eastern Europe. Exploring the role of FGFR2b protein overexpression in gastric cancer represents an exciting potential for targeted therapy.